CHF is whether revascularization might substantially improve LV systolic function in patients
with significant areas of hibernation. 20 The definition and best means of detecting …

Candesartan cilexetil is the prodrug of candesartan, an angiotensin II receptor antagonist.
Candesartan binds selectively and non‐competitively to the angiotensin II receptor type 1 …

Objective To evaluate the effect of angiotensin receptor blockers on the risk of myocardial
infarction in patients at risk for cardiovascular events. Design Systematic review of controlled …

Background: Candesartan cilexetil is a new angiotensin II receptor blocker with a high
affinity for the angiotensin II‐subtype 1 receptor. Aims: This 6‐month study examined the …

Background: Interleukin-6 (IL-6) and tumor necrosis factor alpha (TNF-α) levels increase
after acute myocardial infarction (AMI) in humans. Experimental data suggest that these …

Blockade of the renin–angiotensin system by angiotensin converting enzyme (ACE)
inhibitors reduces mortality and morbidity in patients post-myocardial infarction as well as in …

Background and objective Angiotensin II type 1 receptor antagonists (ARBs) are widely used
as a substitute for angiotensin-converting enzyme inhibitors (ACEIs) to treat patients without …

Angiotensin receptor blockers (ARBs) reduce adverse left ventricular (LV) remodeling and
improve LV function and survival when started postmyocardial infarction (MI). ARBs also …

In this study we evaluated the effect of a dual blockade with enalapril and losartan on the
reduction of overt macroproteinuria and its potential mechanism (s) in hypertensive patients …

Background: Heart failure with preserved systolic left ventricular function is a major cause of
cardiac disability. Objectives: To examine the prevalence, characteristics and late clinical …